Dr Reddy’s Laboratories: Global pharmaceutical company, India
 
 
 
 
 
Global pharmaceutical and drug development company from India, 

operating in over 100 countries worldwide.
  Quick Links
   Newsroom
   Global Presence
   Shareholder's Information
   Join Dr. Reddy’s
 
Transparency
                is the key

  Corporate Governance

Companies listed on the New York Stock Exchange (the NYSE) must comply with certain standards of corporate governance as mentioned in Section 303A of the NYSE's Listed Company Manual. Listed companies that are foreign private issuers (as the term is defined in Rule 3b-4 under the Exchange Act) are permitted to follow home country practices in lieu of the provisions of this Section 303A, except that such companies are required to comply with the requirements of Sections 303A.06, 303A.11 and 303A.12(b) and (c). As per these requirements, a company must

  1. Establish an independent audit committee that has specified responsibilities;
  2. Provide prompt certification by its chief executive officer of any material non-compliance with any corporate governance rules;
  3. Provide periodic written affirmations to the NYSE with respect to its corporate governance practices; and
  4. Provide a brief description of significant differences between its corporate governance practices and those followed by U.S. companies.
The following table compares our principal corporate governance practices to those required of U.S. NYSE listed companies.

Standard for U.S. NYSE Listed Companies

Our practices

Listed companies must have a majority of 'independent directors', as defined by the NYSE.
Six of our nine directors are 'independent directors', as defined by the NYSE.
The non-management directors of each listed company must meet at regularly scheduled executive sessions without management.
Our non-management directors meet periodically without management directors in scheduled executive sessions.
Listed companies must have a nominating/corporate governance committee composed entirely of independent directors. The nominating/corporate governance committee must have a written charter that addresses the committee's purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee.
We have a Nomination Committee composed entirely of independent directors that meets these requirements. The committee has a written charter that meets these requirements. We do not have the practice of evaluating the performance of the Nomination Committee.
Listed companies must have a compensation committee composed entirely of independent directors. The compensation committee must have a written charter that addresses the committee's purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee. We have a Compensation Committee composed entirely of independent directors that meets these requirements. The committee has a written charter that meets these requirements. We do not have the practice of evaluating the performance of Compensation Committee.
Listed companies must have an audit committee that satisfies the requirements of Rule 10A-3 under the Exchange Act. Our Audit Committee satisfies the requirements of Rule 10A-3 under the Exchange Act.
The audit committee must have a minimum of three members, all being independent directors.

The audit committee must have a written charter that addresses the committee's purpose and responsibilities, subject to the minimum purpose and responsibilities established by the NYSE, and an annual evaluation of the committee.

Each listed company must have an internal audit function.
We have an Audit Committee composed of five members, all being independent directors. The committee has a written charter that meets these requirements. We also have an internal audit function. We do not have the practice of evaluating the performance of our Audit Committee
Shareholders must be given the opportunity to vote on all equity-compensation plans and material revisions thereto, with limited exceptions. Our Employee Stock-Option Plan has been approved by our shareholders.

Listed companies must adopt and disclose corporate governance guidelines.

We have not adopted corporate governance guidelines.

All listed companies, U.S. and foreign, must adopt and disclose a code of business conduct and ethics for directors, officers and employees, and promptly disclose any waivers of the code for directors or executive officers.

Details on our Code of Business Conduct and Ethics are given under Item 16.B.
Listed foreign private issuers must disclose any significant ways in which their corporate governance practices differ from those followed by domestic companies under NYSE listing standards. This requirement is being addressed by way of this table.
Each listed company CEO must certify to the NYSE each year that he or she is not aware of any violation by the company of NYSE corporate governance listing standards, qualifying the certification to the extent necessary.
We filed our most recent written certification on October 11, 2006.
Each listed company CEO must promptly notify the NYSE in writing after any executive officer of the listed company becomes aware of any material non-compliance with any applicable provisions of this Section 303A.
There are no such instances.
Each listed company must submit an executed Written Affirmation annually to the NYSE. In addition, each listed company must submit an interim Written Affirmation each time a change occurs to the board or any of the committees subject to Section 303A. The annual and interim Written Affirmations must be in the form specified by the NYSE.
We filed our most recent Written Affirmation on October 11, 2006.
  Triple Bottom Line
  Annual Report 2007
areport
  Key Milestones
  Sustainability Report
 
Designed by
© 2001 - 2008 Dr. Reddy's Laboratories Ltd. All rights reserved
Site best viewed at 800x600 resolution